Dr. Daria Mochly-Rosen is the George D. Smith Professor of Translational Medicine, Professor at the Department of Chemical and Systems Biology and the Senior Associate Dean for Research at Stanford University, School of Medicine.
At her laboratory at Stanford, she leads a multi-disciplinary group that spans basic to translational research. She has taught drug discovery classes for the past 20 years and is the director of SPARK At Stanford, a drug and diagnostic development program that she established in 2006 to help translate early academic discoveries to products that impact human health.
Recent research in her lab focuses on determining the role of aldehyde dehydrogenases, a family of detoxifying enzymes that are involved in a variety of human diseases. Her laboratory identified small molecule activators and inhibitors of individual members of this family, and they use them to determine how these enzymes contribute to signal transduction in normal and disease states. These early studies led to founding ALDEA Pharmaceuticals in 2011.
Another major research focus of the lab involves the rational design of peptides that interfere with protein-protein interactions and their use in the study of intracellular signal transduction in normal and disease states. Early studies for the lab led to her founding KAI Pharmaceuticals, Inc. in 2002 with Dr. Leon Chen. For the first year, she was KAI's Chief Scientific Officer, and then served as the Chairperson of the Scientific Advisory Board and Director, until 2012, when KAI was acquired by Amgen (with $315 M in cash).
Dr. Mochly-Rosen holds about twenty issued patents, several additional patents pending and has authored over 200 publications. She has served on several scientific advisory boards and has been a Fellow in the Council on Basic Cardiovascular Sciences of the American Heart Association, a Founding Fellow of the International Society of Heart Research and a recipient of a number of prestigious awards.
Dr. Mochly-Rosen received her B.Sc. in Life Sciences from Tel Aviv University and her Ph.D. in Chemical Immunology from the Weizmann Institute of Science in Rehovot, Israel. She completed a postdoctoral fellowship in the Department of Biochemistry at the University of California, Berkeley and spent seven years at the University of California, San Francisco, prior to joining Stanford University in 1993.